Real World Registry Assessing the Clinical Use of the Bard UltraScore Forced Focus PTA Balloon

NCT ID: NCT03193619

Last Updated: 2024-03-28

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

350 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-03-28

Study Completion Date

2022-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to assess the clinical use of the Bard® UltraScore™ Focused Force PTA balloon in a heterogeneous patient population in a real world, on-label clinical application.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The registry is a prospective, multi-center, single-arm, real-world study to assess the clinical use of the Bard® UltraScore™ Focused Force PTA balloon for the treatment of stenotic lesions of the superficial femoral artery (SFA), popliteal artery, and infra-popliteal arteries (posterior tibial, anterior tibial and peroneal arteries). Follow-up for all treated subjects will be performed at hospital discharge, 30 days, and 6 and 12 months post-index procedure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Arterial Disease Peripheral Vascular Diseases Arterial Occlusive Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PTA-UltraScore Focused Force PTA balloon

Treatment with the UltraScore Focused Force PTA balloon will be per the investigational site's standard of care and adhering to the IFU.

PTA (UltraScore Focused Force PTA Balloon)

Intervention Type DEVICE

Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough.

The UltraScore Focused Force PTA balloon through the blood vessel to the narrowed area to be treated.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PTA (UltraScore Focused Force PTA Balloon)

Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough.

The UltraScore Focused Force PTA balloon through the blood vessel to the narrowed area to be treated.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject must voluntarily sign and date the Informed Consent Form (ICF) prior to collection of study data or performance of study procedures.
2. Subject must be either a male or non-pregnant female ≥ 21 years of age with an expected lifespan sufficient to allow for completion of all study procedures.
3. Subject must be willing to comply with the protocol requirements, including the follow-up procedures.
4. Subject must have a target lesion (de novo lesion or prior failed treatment) that can be treated with the UltraScore™ Focused Force PTA balloon according to the Instructions for Use (IFU). Only a target lesion in the SFA, popliteal, or infra-popliteal arteries (posterior tibial, anterior tibial, or peroneal arteries) may be treated for this study.
5. Subject must have an Above the Knee (ATK) or Below the Knee (BTK) target lesion with at least one vessel run-off.
6. The target lesion must be able to be crossed using a guidewire (use of chronic total occlusion (CTO) or atherectomy is allowed).

Exclusion Criteria

1. Subjects that are to receive one or more stents as adjunctive therapy at the target lesion (bail out stenting is allowed).
2. The subject has a single target lesion that involves both ATK and BTK arteries.
3. The subject has a target lesion in a previously placed stent or stent graft (in-stent restenosis).
4. The subject has a lesion, which in the opinion of the Investigator, would preclude safe use of the UltraScore™ Focused Force PTA balloon.
5. The subject has a flow limiting dissection at the target lesion prior to use of the UltraScore™ Focused Force PTA balloon.
6. The subject has acute limb ischemia.
7. The subject has been assessed Rutherford category 6.
8. The subject has a known allergy or sensitivity to contrast media, which cannot be adequately pre-medicated.
9. The subject has another medical condition or is currently participating in an investigational drug or another device study that, in the opinion of the Investigator, may cause him/her to be non-compliant with the protocol, confound the data interpretation, or is associated with a life expectancy insufficient to allow for the completion of study procedures and follow-up.
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

C. R. Bard

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Craig Walker, MD

Role: PRINCIPAL_INVESTIGATOR

Cardiovascular Institute of the South (CIS) Clinical Research Corporation

Robert Beasley, MD

Role: PRINCIPAL_INVESTIGATOR

Icahn School of Medicine at Mount Sinai

Miguel Montero, MD

Role: PRINCIPAL_INVESTIGATOR

Baylor St. Luke's College of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St. Luke's Hospital- Phoenix

Phoenix, Arizona, United States

Site Status

Health One Denver Heart

Denver, Colorado, United States

Site Status

Mount Sinai Medical Center

Miami Beach, Florida, United States

Site Status

St. Joseph Hospital

Fort Wayne, Indiana, United States

Site Status

Community Hospital Munster Research Foundation

Munster, Indiana, United States

Site Status

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States

Site Status

University of Kentucky

Lexington, Kentucky, United States

Site Status

Willis Knighton Medical Center

Bossier City, Louisiana, United States

Site Status

CIS Clinical Research Corporation

Lafayette, Louisiana, United States

Site Status

MedStar Health Research Institute

Annapolis, Maryland, United States

Site Status

Beth Israel Deaconess Medical Center, Inc

Boston, Massachusetts, United States

Site Status

Providence-Providence Park Hospital

Southfield, Michigan, United States

Site Status

SSM DePaul Health Center

Bridgeton, Missouri, United States

Site Status

St. Louis Univeristy

St Louis, Missouri, United States

Site Status

Methodist Health System

Omaha, Nebraska, United States

Site Status

Mount Sinai School of Medicine

New York, New York, United States

Site Status

Staten Island University Hospital

Staten Island, New York, United States

Site Status

Montefiore Medical Center

The Bronx, New York, United States

Site Status

East Carolina University

Greenville, North Carolina, United States

Site Status

Rex Hospital, Inc

Raleigh, North Carolina, United States

Site Status

Coastal Surgery Specialists

Wilmington, North Carolina, United States

Site Status

Oregon Health & Science University

Portland, Oregon, United States

Site Status

US Cardiovascular Jefferson Hills

Jefferson Hills, Pennsylvania, United States

Site Status

Pinnacle Health Cardiovascular Institute

Wormleysburg, Pennsylvania, United States

Site Status

Vascular Access Solutions

Orangeburg, South Carolina, United States

Site Status

Stern Cardiovascular Foundation, Inc

Germantown, Tennessee, United States

Site Status

Cardiothoracic and Vascular Surgeons

Austin, Texas, United States

Site Status

Baylor St. Luke's Health College of Medicine

Houston, Texas, United States

Site Status

The Methodist Hospital Research Institute dba Houston Methodist Research Institute

Houston, Texas, United States

Site Status

Texas Tech University Health Science Center/University Medical Center

Lubbock, Texas, United States

Site Status

HSHS St. Vincent Hospital

Green Bay, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BPV-16-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Lutonix Global SFA Registry
NCT01864278 COMPLETED